Skip to content
10-Q

Quarterly Report

ANAVEX LIFE SCIENCES CORP. AVXL

0001731122-24-001207

← back to feed
Filed
Aug 6, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Aug 6, 2024 84.8M sh
Cash And Equivalents Q3 2024 · Jun 30, 2024 $138.76M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $151.02M
Total Liabilities Q3 2024 · Jun 30, 2024 $11.75M
Total Liabilities Q3 2024 · Sep 30, 2023 $12.53M
Total Assets Q3 2024 · Jun 30, 2024 $141.54M
Total Assets Q3 2024 · Sep 30, 2023 $154.39M
Shares Diluted Q3 2024 · Jun 30, 2023 80.88M sh
Shares Diluted Q3 2024 · Jun 30, 2023 79.05M sh
Operating Cash Flow restated Q3 2024 · Jun 30, 2023 −$21.94M
Stockholders Equity restated Q3 2024 · Jun 30, 2023 $146.76M
Stockholders Equity restated Q3 2024 · Mar 31, 2023 $145.17M
Stockholders Equity restated Q3 2024 · Sep 30, 2022 $142.49M
Eps Diluted Q3 2024 · Jun 30, 2023 −$0.14
Eps Diluted Q3 2024 · Jun 30, 2023 −$0.47
Eps Basic Q3 2024 · Jun 30, 2023 −$0.14
Eps Basic Q3 2024 · Jun 30, 2023 −$0.47
Rd Expense restated Q3 2024 · Jun 30, 2023 $10.28M
Rd Expense restated Q3 2024 · Jun 30, 2023 $33.66M
Net Income restated Q3 2024 · Jun 30, 2023 −$11.28M
Net Income restated Q3 2024 · Jun 30, 2023 −$37.36M
Operating Income restated Q3 2024 · Jun 30, 2023 −$13.53M
Operating Income restated Q3 2024 · Jun 30, 2023 −$43.1M